MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients
Status:
Completed
Trial end date:
2020-11-19
Target enrollment:
Participant gender:
Summary
This is a phase II open-label randomized clinical trial of MK-3475 (Pembrolizumab) on
previously treated non-small cell lung cancer (NSCLC) patients . This drug has shown to allow
partial response according to the immune-related response criteria and the response
evaluation criteria in solid tumors (RECIST). The main endpoint is to compare the overall
response rate (ORR) of MK-3475 with docetaxel or docetaxel alone in patients with advanced
NSCLC.